Methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection

  • Email
  • Help
Current effective version

Draft reflection paper

Reference numberEMA/CHMP/446337/2011
KeywordsClinical trial designs, enriched design, genomic biomarkers (GBMS), hybrid design, predictive markers, pharmacogenomics, retrospective data analyses
DescriptionThis document highlights key principles that should be considered by stakeholders with focus on use of genomic biomarkers in relation to patient selection and associated issues with trial methodology.

How helpful is this page?

Average rating:

 Based on 26 ratings

Add your rating:

See all ratings
5 ratings
5 ratings
5 ratings
5 ratings
6 ratings

Tell us more